Compare LEA & HALO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LEA | HALO |
|---|---|---|
| Founded | 1917 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.2B | 8.1B |
| IPO Year | 1994 | 2001 |
| Metric | LEA | HALO |
|---|---|---|
| Price | $135.66 | $74.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 14 | 11 |
| Target Price | ★ $132.21 | $78.64 |
| AVG Volume (30 Days) | 677.0K | ★ 1.6M |
| Earning Date | 05-01-2026 | 05-05-2026 |
| Dividend Yield | ★ 2.49% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 3.34 | 1.22 |
| Revenue | ★ $23,259,100,000.00 | $151,862,000.00 |
| Revenue This Year | $2.50 | $28.24 |
| Revenue Next Year | $3.12 | $12.56 |
| P/E Ratio | ★ $41.38 | $59.53 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $91.67 | $51.06 |
| 52 Week High | $150.33 | $82.22 |
| Indicator | LEA | HALO |
|---|---|---|
| Relative Strength Index (RSI) | 44.11 | 66.87 |
| Support Level | $115.63 | $62.53 |
| Resistance Level | $141.92 | $79.50 |
| Average True Range (ATR) | 4.06 | 2.20 |
| MACD | -1.29 | 0.30 |
| Stochastic Oscillator | 9.91 | 84.09 |
Lear Corp designs, develops, and manufactures automotive seating and electrical systems and components. The company has two reporting segments Seating and E-Systems. Seating components include frames and mechanisms, covers (leather and woven fabric), seat heating and cooling, foam, and headrests. Automotive electrical distribution and connection systems and electronic systems include wiring harnesses, terminals and connectors, on-board battery chargers, high-voltage battery management systems. The company earns majority of its revenue from the seating segment.
Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies. The company seeks to create therapies focused on human enzymes that alter tumors. Halozyme focuses on developing its proprietary products in therapeutic areas with a focus on oncology, and licensing its technology to biopharmaceutical companies to collaboratively develop products. ENHANZE drug delivery technology was introduced with the proprietary enzyme rHuPH20, to facilitate the subcutaneous delivery of injected drugs and fluids, with the goal of improving the patient experience with rapid SC delivery and reduced treatment burden. The company's operations are based in the United States, with minimal long-lived assets located internationally.